News
Since the introduction of imatinib mesylate, the role of allogeneic hematopoietic cell transplantation (allo-HCT) for CML has essentially been reserved for patients with advanced disease or ...
Indeed a recent report suggested that imatinib-induced myelosuppression in patients with chronic phase CML may be associated with lower rates of cytogenetic responses at 1 year. 5 Another report in ...
Our experience confirms the safety of Imatinib therapy preceding allogeneic SCT, as reported by some recent publications. 7, 8, 9 Pre-treatment with Glivec for CML or Ph+ ALL does not seem to ...
After a median follow-up of 54 months, 72% of the 553 patients who were initially randomized to imatinib remain on treatment, Dr. Druker said. He noted that 5% had discontinued due to adverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results